284 related articles for article (PubMed ID: 16937336)
1. Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects.
Choi YH; Kim SG; Lee MG
J Pharm Sci; 2006 Nov; 95(11):2543-52. PubMed ID: 16937336
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Shim HJ; Kim YC; Park KJ; Kim DS; Kwon JW; Kim WB; Lee MG
J Pharm Sci; 2003 Nov; 92(11):2185-95. PubMed ID: 14603504
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects.
Han KS; Lee MG
Drug Metab Dispos; 1999 Feb; 27(2):221-6. PubMed ID: 9929506
[TBL] [Abstract][Full Text] [Related]
4. Hepatic and intestinal first-pass effects of oltipraz in rats.
Bae SK; Kim JW; Kim YH; Kim YG; Kim SG; Lee MG
Biopharm Drug Dispos; 2005 May; 26(4):129-34. PubMed ID: 15744718
[TBL] [Abstract][Full Text] [Related]
5. Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Lee MH; Bae SK; Kim EJ; Kim YG; Kim SO; Lee DH; Lim H; Yoo SE; Lee MG
J Pharm Sci; 2003 Jan; 92(1):190-201. PubMed ID: 12486695
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
Kim SH; Lee MG
Life Sci; 2002 Feb; 70(11):1299-315. PubMed ID: 11883708
[TBL] [Abstract][Full Text] [Related]
7. Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR-60436, after intravenous and oral administration to rats: gastrointestinal first-pass effect.
Yu SY; Bae SK; Kim EJ; Kim YG; Kim SO; Lee DH; Lim H; Lee MG
J Pharm Sci; 2003 Aug; 92(8):1592-603. PubMed ID: 12884246
[TBL] [Abstract][Full Text] [Related]
8. Dose-independent pharmacokinetics of a candidate for diabetic neuropathy, SR-4668, after intravenous and oral administration to rats: Intestinal first-pass effect.
Kim EJ; Bae SK; Kim HJ; Kim YG; Kim SO; Lee DH; Lim H; Lee MG
J Pharm Sci; 2003 May; 92(5):1112-24. PubMed ID: 12712431
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal first-pass effect of YJA-20379-8, a new reversible proton pump inhibitor, in rats.
Kim J; Kim EJ; Han KS; Chang MS; Lee MG
J Pharm Pharmacol; 1999 Sep; 51(9):1031-6. PubMed ID: 10528986
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: contribution of intestinal first-pass effect to low bioavailability.
Lee JH; Lee MG
J Pharm Pharm Sci; 2007; 10(1):37-50. PubMed ID: 17498392
[TBL] [Abstract][Full Text] [Related]
11. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability.
Yang SH; Lee MG
Int J Pharm; 2007 Mar; 332(1-2):17-23. PubMed ID: 17157458
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects.
Shin HS; Bae SK; Lee MG
Int J Pharm; 2006 Aug; 320(1-2):64-70. PubMed ID: 16730145
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect.
Bae SK; Yang KH; Aryal DK; Kim YG; Lee MG
J Pharm Sci; 2009 Apr; 98(4):1587-601. PubMed ID: 18780336
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect.
Shin JH; Choi KY; Kim YC; Lee MG
Antimicrob Agents Chemother; 2004 May; 48(5):1756-62. PubMed ID: 15105131
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats.
Han KS; Kim YG; Yoo JK; Lee JW; Lee MG
Biopharm Drug Dispos; 1998 Nov; 19(8):493-500. PubMed ID: 9840211
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effect.
Kang HE; Cho YK; Jung HY; Choi KY; Sohn SI; Baek SR; Lee MG
Xenobiotica; 2009 Jun; 39(6):465-75. PubMed ID: 19480552
[TBL] [Abstract][Full Text] [Related]
17. Effects of bacterial lipopolysaccharide on the pharmacokinetics of metformin in rats.
Choi YH; Lee I; Lee MG
Int J Pharm; 2007 Jun; 337(1-2):194-201. PubMed ID: 17275228
[TBL] [Abstract][Full Text] [Related]
18. Hepatic and gastrointestinal first-pass effects of vitexin-4″-O-glucoside in rats.
Chen Y; Zhang W; Li D; Ai J; Meng Y; Ying X; Kang T
J Pharm Pharmacol; 2013 Oct; 65(10):1500-7. PubMed ID: 24028617
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent pharmacokinetics of a new reversible proton pump inhibitor, DBM-819, after intravenous and oral administration to rats: hepatic first-pass effect.
Kim EJ; Kim SO; Lee DH; Lim H; Lee MG
Biopharm Drug Dispos; 2001 Apr; 22(3):119-28. PubMed ID: 11745914
[TBL] [Abstract][Full Text] [Related]
20. Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability.
Yang SH; Lee MG
Biopharm Drug Dispos; 2008 Oct; 29(7):414-26. PubMed ID: 18697186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
